Lilly Launches KwikPen(TM) for Humalog(R) and Humalog Mixtures
February 21 2008 - 8:00AM
PR Newswire (US)
New prefilled insulin pen caps Lilly's unprecedented year of device
innovation INDIANAPOLIS, Feb. 21 /PRNewswire/ -- Completing an
unprecedented year of innovation in insulin delivery devices, Eli
Lilly and Company (LLY) today announced the launch of KwikPen(TM),
a new insulin pen prefilled with the Humalog(R) (insulin lispro
injection [rDNA origin]) brand of insulins. KwikPen is the third
new insulin pen Lilly has launched in the last 12 months to help
improve the daily management of diabetes, following the successful
launches in 2007 of HumaPen(R) MEMOIR(TM) -- the world's first
digital insulin pen with memory -- and HumaPen(R) LUXURA(TM) HD, a
reusable pen for people who need insulin dosing in smaller
increments. (Photo:
http://www.newscom.com/cgi-bin/prnh/20080221/NYTH010 ) KwikPen is a
prefilled insulin pen designed to be convenient, easy to use and
discreet. KwikPen's design can help fit a mealtime insulin, such as
Humalog, into the daily lives and routines of people with diabetes.
KwikPen is now available by prescription in pharmacies prefilled
with the Humalog brand of insulins, including Humalog, Humalog(R)
Mix75/25(TM) (75% insulin lispro protamine suspension, 25% insulin
lispro injection [rDNA origin]) and Humalog(R) Mix50/50(TM) (50%
insulin lispro protamine suspension, 50% insulin lispro injection
[rDNA origin]). The Humalog brand of insulins are indicated for use
in patients with diabetes to control high blood sugar. Lilly's
original Humalog and Humalog Mixtures prefilled pens are also
available. Patients using the original Humalog and Humalog Mixtures
prefilled pen do not need to convert at this time unless they
choose to do so in consultation with a health care professional.
"KwikPen, prefilled with Humalog and Humalog Mixtures, provides
people with diabetes an exciting new option for accurate insulin
dosing with the convenience of an easy-to-use prefilled pen," said
Matt Beebe, Humalog Brand Leader, Lilly USA. "We know living with
diabetes presents challenges day-by- day, meal-by-meal. At Lilly,
our goal is to provide innovative therapies that help patients
accurately and discreetly manage their use of mealtime insulin, as
well as practical solutions beyond therapy that help patients live
successfully with diabetes." Last year, Lilly launched two
innovative reusable pens -- HumaPen MEMOIR and HumaPen LUXURA HD -
to help address those diabetes management needs. HumaPen MEMOIR,
available by prescription nationwide for use with Humalog, presents
sophisticated technology and features in a consumer-friendly "push-
to-know" digital display that allows patients to record and review
their last 16 insulin doses, including the priming doses. Many
insulin users need multiple injections per day, so the ability to
record doses and the time of the dose may help simplify the daily
management of diabetes. This is especially important for both
patients and physicians when developing a diabetes treatment plan
that utilizes accurate recording of mealtime doses. HumaPen LUXURA
HD is a reusable pen that can deliver Humalog in half-unit
increments from 1-to-30 units. Also available by prescription, this
type of pen may be attractive to people with diabetes that do not
need large amounts of insulin, or parents of some children with
diabetes. To learn more about insulin delivery devices for use with
the Humalog brand of insulins, visit http://www.humalog.com/.
Indication Humalog, Humalog Mix75/25 and Humalog Mix50/50 are for
use in patients with diabetes to control high blood sugar. Humalog
should be used with a longer-acting insulin, except when used in
combination with sulfonylureas in patients with type 2 diabetes.
Important safety information Humalog insulins should not be used
during episodes of hypoglycemia and in patients sensitive to
Humalog or one of its excipients. The safety and effectiveness of
Humalog in patients less than 3 years of age have not been
established. Safety and effectiveness of Humalog Mix50/50 and
Humalog Mix75/25 in patients less than 18 years of age have not
been established. There are no clinical studies of the use of
Humalog insulins in pregnancy or nursing mothers. A potential side
effect associated with the use of all insulins is low blood sugar.
Low blood sugar can happen suddenly and symptoms may be different
for each person and may change from time to time. Know your
symptoms of low blood sugar. Severe low blood sugar can cause
seizures and be life- threatening. Follow your health care
provider's instruction for treating low blood sugar and regularly
checking blood sugar levels. Other side effects may include: weight
gain, low blood potassium, changes in fat tissue at the site of
injection, and allergic reactions, both at the injection site and
over the whole body. Whole body allergic reactions are less common,
but may be life- threatening. Starting or changing insulin therapy
should be done cautiously and only under medical supervision.
Humalog and Humalog mixtures start lowering blood sugar more
quickly than regular human insulin, allowing for convenient dosing
immediately before a meal (within 15 minutes). Humalog can even be
taken immediately after your meal. Because Humalog is a mealtime
insulin, you may also need a longer-acting insulin to get the best
blood sugar control (except when using an insulin pump). About
Diabetes According to the Centers for Disease Control and
Prevention, diabetes affects nearly 21 million Americans; of that,
nearly one-third, or approximately six million people, do not know
they have the disease. Diabetes is the sixth leading cause of death
in the United States and costs approximately $132 billion per year
in direct and indirect medical expenses. About Lilly Diabetes
Through a long-standing commitment to diabetes care, Lilly provides
patients with breakthrough treatments that enable them to live
longer, healthier and fuller lives. Since 1923, Lilly has been the
industry leader in pioneering therapies to help health care
professionals improve the lives of people with diabetes, and
research continues on innovative medicines to address the unmet
needs of patients. For more information about Lilly's diabetes
products, visit http://www.lillydiabetes.com/. About Eli Lilly and
Company Lilly, a leading innovation-driven corporation, is
developing a growing portfolio of first-in-class and best-in-class
pharmaceutical products by applying the latest research from its
own worldwide laboratories and from collaborations with eminent
scientific organizations. Headquartered in Indianapolis, Ind.,
Lilly provides answers -- through medicines and information -- for
some of the world's most urgent medical needs. Information about
Lilly is available at http://www.lilly.com/. Humalog(R) is a
registered trademark of Eli Lilly and Company. Humalog(R)
Mix75/25(TM) and Humalog(R) Mix50/50(TM) are trademarks of Eli
Lilly and Company. Humalog(R) KwikPen(TM), HumaPen(R) MEMOIR(TM)
and HumaPen(R) LUXURA(TM) HD are trademarks of Eli Lilly and
Company. P-LLY Contact Information: J. Scott MacGregor 317-651-1494
office; 317-440-4699 cell
http://www.newscom.com/cgi-bin/prnh/20080221/NYTH010
http://photoarchive.ap.org/ DATASOURCE: Eli Lilly and Company
CONTACT: J. Scott MacGregor, +1-317-651-1494, cell: +1-317-440-4699
Web site: http://www.lilly.com/ http://www.lillydiabetes.com/
http://www.humalog.com/
Copyright